EPAS1 and renal cell carcinoma: For instance, two small molecule HIF-2α inhibitors, MD6482 (also known as PT2977) and PT2385, exhibited promising activities in experimental models, and based on the results of clinical testing in participants with advanced renal cell carcinoma, MK6482 became the first FDA-approved HIF-2α inhibitor (1).